SG Americas Securities
VRDN icon

SG Americas Securities’s Viridian Therapeutics VRDN Stock Holding History

SG Americas Securities’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
109,073
+49,029
+82% +$790K ﹤0.01% 1500
2026
Q1 		$1.17M Buy
60,044
+26,956
+81% +$801K ﹤0.01% 1660
2025
Q4 		$1.03M Sell
33,088
-29,030
-47% -$796K ﹤0.01% 1992
2025
Q3 		$1.34M Buy
62,118
+49,981
+412% +$901K ﹤0.01% 1211
2025
Q2 		$170K Sell
12,137
-19,835
-62% -$269K ﹤0.01% 2370
2025
Q1 		$431K Buy
31,972
+887
+3% +$15.1K ﹤0.01% 1896
2024
Q4 		$596K Buy
31,085
+14,644
+89% +$318K ﹤0.01% 1182
2024
Q3 		$374K Sell
16,441
-29,615
-64% -$484K ﹤0.01% 1951
2024
Q2 		$599K Buy
+46,056
New +$638K ﹤0.01% 1573
2024
Q1 		– Sell
-40,588
Closed -$884K – 3473
2023
Q4 		$884K Sell
40,588
-62,079
-60% -$980K 0.01% 1090
2023
Q3 		$1.57M Buy
102,667
+61,676
+150% +$1.18M 0.02% 911
2023
Q2 		$975K Buy
40,991
+30,732
+300% +$788K 0.01% 1067
2023
Q1 		$261K Buy
10,259
+3,690
+56% +$118K ﹤0.01% 2217
2022
Q4 		$192K Sell
6,569
-1,713
-21% -$39.5K ﹤0.01% 2227
2022
Q3 		$170K Buy
+8,282
New +$149K ﹤0.01% 2446
2019
Q1 		– Sell
-6,622
Closed -$301K – 3659
2018
Q4 		$301K Buy
6,622
+445
+7% +$25.7K ﹤0.01% 2165
2018
Q3 		$517K Buy
+6,177
New +$583K ﹤0.01% 2097
2017
Q4 		– Sell
-1,819
Closed -$250K – 3672
2017
Q3 		$250K Buy
+1,819
New +$306K ﹤0.01% 2400

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SG Americas Securities's VRDN Position: Q2 2026 in Review

SG Americas Securities increased its Viridian Therapeutics (VRDN) stake by 82% in Q2 2026, buying an estimated $790K and bringing the position to 109,073 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

SG Americas Securities first reported a position in VRDN in Q3 2017 and has held it in 18 quarters since. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • SG Americas Securities held 109,073 shares of Viridian Therapeutics worth $2M as of Q2 2026.
  • SG Americas Securities bought 49,029 Viridian Therapeutics shares in Q2 2026, an estimated $790K.
  • Viridian Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1500 holding.
  • SG Americas Securities first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 18 quarters since.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.